Myths vs facts: CYP2C19 and menopause

The link between CYP2C19 and menopause is scientifically weak. CYP2C19 is a liver enzyme that metabolizes drugs like clopidogrel and certain antidepressants. Genetic variants (*2, *3, *17) determine metabolizer status (poor, intermediate, normal, rapid, ultrarapid). During menopause, hormonal changes occur, but there is no strong evidence that CYP2C19 variants directly influence menopause onset, severity of symptoms, or response to hormone therapy. Some mechanistic studies suggest CYP2C19 may be involved in estrogen hydroxylation, but effect sizes are small and not clinically actionable. Myth: A DNA test can predict menopause timing or guide hormone replacement. Fact: CYP2C19 genotyping may be relevant for drug dosing (e.g., antidepressants for mood symptoms), but not for menopause management per se. Evidence is mechanistic/observational, not interventional. Lifestyle, diet, and clinical monitoring remain key. Caution: Do not self-supplement based on genetic results.